BrightSpring Health Services Reports Robust Q1, Raises 2026 Revenue & EBITDA Outlook
BTSG has more than doubled off its 52-week low of $17.12 on elevated volume (3.0× avg).
Summary
BrightSpring Health Services reported strong first-quarter 2026 financial results, significantly exceeding prior-year figures and prompting an increase in its full-year 2026 revenue and Adjusted EBITDA guidance. Net revenue surged 25.6% to $3.614 billion, while Adjusted EBITDA jumped 44.8% to $190 million, and net income dramatically rose to $74 million from $9 million year-over-year. This robust performance builds on the strong full-year 2025 results and improved debt profile previously reported in the company's 10-K. The company also noted the completion of its secondary offering and a $60 million share repurchase in March, aligning with prior disclosures. The raised guidance, coupled with strong operational metrics and an improved leverage ratio, signals significant positive momentum and management confidence, which is highly material for investors, especially with the stock trading near its 52-week high.
At the time of this announcement, BTSG was trading at $49.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.3B. The 52-week trading range was $17.12 to $48.97. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.